However, the Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study reported that empagliflozin, which promotes excretion of glucose (and sodium) by inhibiting sodium–glucose cotransporter 2 (SGLT-2) in the kidneys, brought about a 34% reduction in the risk of hospitalisation for heart-failure [6]. Here, SLC5A2 is linked to heart failure.